Ventyx Biosciences, INC

Ventyx Biosciences, Inc. has completed its merger with Eli Lilly and Company, becoming a wholly-owned subsidiary.

Ventyx Biosciences, Inc. stockholders have approved the Agreement and Plan of Merger with Eli Lilly and Company, paving the way for Ventyx to become a wholly owned subsidiary.

Ventyx Biosciences provides supplemental disclosures on its pending $14.00 per share cash merger with Eli Lilly, including financial analyses, partnership projections, and new stockholder lawsuits.

Ventyx Biosciences' Board approved cash bonus awards for key executives in lieu of equity grants, tied to the anticipated merger with Eli Lilly and Company.

Eli Lilly and Company will acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company, for approximately $1.2 billion in an all-cash transaction.

Ventyx Biosciences announced its third quarter 2025 financial results and highlighted positive Phase 2 data for its NLRP3 inhibitor VTX3232 in cardiovascular risk factors and Parkinson's disease.

Ventyx Biosciences reported reduced net losses in Q3 2025, driven by lower R&D expenses, while advancing its NLRP3 inhibitor pipeline and seeking partners for IBD programs.

Ventyx Biosciences reported a reduced net loss in Q2 2025, driven by decreased R&D expenses, and announced positive clinical data for its VTX3232 Parkinson's trial while seeking partners for other programs.

Ventyx Biosciences announces its Q1 2025 financial results, highlighting progress in its clinical-stage programs targeting autoimmune, inflammatory, and neurodegenerative diseases.

Ventyx Biosciences reports a net loss of $35.2 million for Q3 2024, alongside updates on its clinical programs and financial position.

Ventyx Biosciences reports a net loss of $70.5 million for the first half of 2024, while advancing its clinical programs for inflammatory diseases.

Ventyx Biosciences reports a net loss of $38.6 million for the first quarter of 2024, alongside positive clinical trial updates and a recent private placement raising $95.1 million.

Ventyx Biosciences details its 2024 financial results and provides updates on its clinical-stage pipeline of oral therapies for autoimmune, inflammatory, and neurodegenerative diseases.

Ventyx Biosciences, a clinical-stage biopharmaceutical company, released its full year 2023 results, highlighting progress in its clinical programs and strategic focus on immunology.

Ventyx Biosciences' Senior VP of Finance, Roy Gonzales, disposed of all his common stock and stock options following the company's merger with Eli Lilly and Company.

Director Somu Subramaniam reports disposition of Ventyx Biosciences shares and options following its acquisition by Eli Lilly for $14.00 per share.

A Ventyx Biosciences director's stock options were either cashed out or cancelled following the company's acquisition by Eli Lilly and Company.

Ventyx Biosciences Chief Operating Officer Matthew Richard Moore's stock options were cancelled and converted to cash following the company's merger with Eli Lilly and Company.

Ventyx Biosciences director Onaiza Cadoret-Manier's stock options were cancelled and converted to cash or no consideration following the acquisition by Eli Lilly and Company.

Ventyx Biosciences Director Allison Hulme's stock options were cancelled as part of the company's acquisition by Eli Lilly and Company, with some converted to cash and others for no consideration.

Ventyx Biosciences filed supplemental disclosures regarding its proposed $14.00 per share cash merger with Eli Lilly, including financial analysis updates, partnership projections, and details on shareholder lawsuits.

Ventyx Biosciences' Board approved cash bonus awards for executives, replacing 2026 equity grants, contingent on the anticipated merger with Eli Lilly and Company.

Ventyx Biosciences has agreed to be acquired by Eli Lilly, a transaction expected to close in the first half of 2026.

Eli Lilly and Company will acquire Ventyx Biosciences, Inc. for $1.2 billion in an all-cash transaction, offering shareholders a 62% premium.

Ventyx Biosciences announced an agreement to be acquired by Eli Lilly, expecting to close the transaction in the first half of 2026.

Ventyx Biosciences announced an agreement to be acquired by Eli Lilly for $14.00 per share in cash, representing a 62% premium.

An insider group, including Somasundaram Subramaniam, has ceased beneficial ownership of Ventyx Biosciences, Inc. following its acquisition by Eli Lilly and Company for $14.00 per share in cash.

Ventyx Biosciences, Inc. has entered into a definitive merger agreement to be acquired by Eli Lilly and Company for $14.00 per common share in cash.

Ventyx Biosciences, Inc. has entered into a definitive merger agreement to be acquired by Eli Lilly and Company for $14.00 per common share in cash.

Ventyx Biosciences CEO Raju Mohan has increased his beneficial ownership in the company to 6.0% through a combination of direct purchases, option exercises, and RSU vesting.

NSV Partners III, L.P., NSV Partners III GP, LLC, and Somasundaram Subramaniam have filed an Amendment No. 13 to their Schedule 13D, detailing a distribution of 1,335,450 Ventyx Biosciences common shares by NSV Investments I, L.P. and the subsequent reduction in their beneficial ownership percentages.

NSV Investments I, L.P. and affiliated entities have updated their beneficial ownership in Ventyx Biosciences, Inc. through an Amendment No. 12 to Schedule 13D, reflecting a distribution of 1.73 million shares to limited partners.

Tang Capital Management and associated entities have reported a 0% beneficial ownership stake in Ventyx Biosciences, Inc.

Affinity Asset Advisors, LLC and Michael Cho report holding 0% of Ventyx Bioscience's common stock as of March 31, 2026.

Glazer Capital, LLC and Paul J. Glazer have filed a Schedule 13G, reporting no beneficial ownership of Ventyx Biosciences, Inc. common stock as of March 31, 2026.

Glazer Capital, LLC and Paul J. Glazer have reported a beneficial ownership of 6.23% in Ventyx Biosciences, Inc. common stock.

Morgan Stanley has filed an amended Schedule 13G, reporting its beneficial ownership in Ventyx Biosciences, Inc. has fallen below the 5% threshold.

Morgan Stanley has reported a 6.0% beneficial ownership stake in Ventyx Biosciences, Inc., holding 4,289,915 common shares as of December 31, 2025.